|
WO2021053389A1
|
|
Methods of treating epileptic patients with fenfluramine
|
|
WO2020176276A1
|
|
A formulation for improving seizure control
|
|
WO2020105005A1
|
|
Methods of treating rett syndrome using fenfluramine
|
|
WO2020112460A1
|
|
A method of treating refractory epilepsy syndromes using fenfluramine enantiomers
|
|
WO2020014075A1
|
|
Fenfluramine for use for treating epilepsy or epileptic encephalopathy in patients without pulmonary hypertension
|
|
US2019380979A1
|
|
Compositions and methods for treating respiratory depression with fenfluramine
|
|
US2019247333A1
|
|
Method of reduction in convulsive seizure frequency
|
|
US2019083425A1
|
|
Formulation for inhibiting formation of 5-ht2b agonists and methods of using same
|
|
WO2019067413A1
|
|
Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations
|
|
US2019091178A1
|
|
Ketogenic diet compatible fenfluramine formulation
|
|
US2019091179A1
|
|
Congnitive function with fenfluramine
|
|
US2019091174A1
|
|
Method of reducing seizure type experienced by a dravet patient
|
|
WO2019216919A1
|
|
Compositions and methods for treating seizure-induced sudden death
|
|
EP3634392A1
|
|
Methods of treating doose syndrome using fenfluramine
|
|
US2018092864A1
|
|
Compositions and methods for treating seizure disorders
|
|
AU2017315273A1
|
|
Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same
|
|
AU2016379345A1
|
|
Metabolism resistant fenfluramine analogs and methods of using the same
|
|
BR112017006219A2
|
|
drug distribution control system
|
